Advanced search

News (72)

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older	26/04	BU
Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain	19/04	AQ
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain	18/04	BU
Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	02/04	AQ
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease	01/04	BU
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	22/03	AQ
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	21/03	BU
Next-in-class combination treatment shows potential in cystic fibrosis	08/02	AQ
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor, Tezacaftor, Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis	06/02	AQ
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis	06/02	BU
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy	13/12	BU
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition	12/12	BU
Vertex Pharmaceuticals - European Commission Approves KAFTRIO in Combination with Ivacaftor for the Treatment of Children with Cystic Fibrosis Ages 2 Through 5	24/11	AQ
Vertex Pharmaceuticals Cystic Fibrosis Treatment Approved for Young Children in EU	23/11	DJ
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5	23/11	BU
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA at the North American Cystic Fibrosis Conference	03/11	AQ
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference	02/11	BU
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting	04/23/04	BU
Vertex Announces Publication of VX-548 Positive Phase 2 Proof-of-Concept Results in New England Journal of Medicine	04/23/04	AQ
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine	03/23/03	BU
European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old	05/23/05	BU
Vertex Pharmaceuticals - Positive Results from Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association Congress	12/23/12	AQ
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress	09/23/09	BU
Vertex Announces U.S. FDA Approval for KALYDECO to Treat Eligible Infants with CF Ages 1 Month and Older	04/23/04	AQ
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older	04/23/04	BU
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations	26/23/26	BU
CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	04/23/04	AQ
CRISPR Therapeutics : Regulation FD Presentation - Form 8-K	03/23/03	PU
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	03/23/03	BU
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin	17/23/17	AQ
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)	16/23/16	BU
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology Annual Meeting and Exposition	12/22/12	AQ
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition	10/22/10	BU
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease	07/22/07	AQ
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)	04/22/04	BU
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference	03/22/03	BU
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months	02/22/02	BU
Vertex Advances VX-548 in Acute and Neuropathic Pain	25/22/25	AQ
Vertex Advances VX-548 in Acute and Neuropathic Pain	22/22/22	BU
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress	13/22/13	AQ
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress	11/22/11	BU
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference	10/22/10	BU
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes	02/22/02	BU
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain	31/22/31	BU
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease	22/22/22	BU

12NextSee all

Companies (9)

TECK RESOURCES LIMITED 27 720 M $

Teck Resources Limited is a Canada-based mining company that operates in copper, zinc, steelmaking coal and energy segment. The Companyâs operations and projects include Antamina, Cardinal River, Carmen de Andacollo, Elkview, Fording River, Fording Rive ...

SIGNATURE EYEWEAR, INC. 6 $

Signature Eyewear, Inc. is an eyewear company. The Company provides eyewear to opticians, optometrists and ophthalmologists. Its brands include Bobby Jones, Carmen Marc Valvo, Cutter & Buck, CEO-V, Dakota Smith, Hart Schaffner Marx, Hickey Freeman, Laura ...

FIBRA PLUS 338 M $

Fibra Plus is a Mexico-based company engaged in the operation of real estate development trust (REIT). The Company focuses on the acquisition, development, management and rental of commercial properties in Mexico. The Company's real estate portfolio compr ...

KNOT OFFSHORE PARTNERS LP 193 M $

KNOT Offshore Partners LP is a United Kingdom-based company that owns, operates and acquires shuttle tankers primarily under long-term charters in the offshore oil production regions of Brazil and the North Sea. The Company's fleet consists of approximate ...

ATICO MINING CORPORATION 21 M $

Atico Mining Corporation is a Canada-based company, focused on exploring, developing, and mining copper and gold projects in Latin America. Its segments include El Roble mine, El Roble exploration and evaluation (E&E), La Plata E&E. Its El Roble mine segm ...

ATLAS CONSOLIDATED MINING AND DEVELOPMENT CORPORATION 321 M $

Atlas Consolidated Mining and Development Corporation is a Philippines-based diversified natural resource-based company. The Company is engaged in metallic mineral exploration and mining. It operates through two segments: mining and non-mining. The mining ...

UNIVANICH PALM OIL 217 M $

Univanich Palm Oil Public Company Limited is a Thailand-based producer of crude palm oils and oil palm seeds. The Company is engaged in oil palm plantations, crushing mills, oil palm research and seed businesses, and an electric power plant with a methane ...

BW OFFSHORE LIMITED 488 M $

BW Offshore Limited is a Bermuda-based holding company, which engineers advanced floating production solutions. The Company has a fleet of approximately three floating, production, storage, and offloading vessels (FPSOs) with the potential to grow. The Co ...

HERENCIA RESOURCES PLC 1 M $

Herencia Resources plc (Herencia) is engaged in mineral exploration and development. The Company holds a portfolio of copper-silver and zinc-silver-lead-copper-gold properties in Chile, South America. The Company's segments include Mineral Exploration and ...

Insiders

Carmen Bozic

Carmen Bozic is Chief Medical Officer & EVP-Medical Affairs at Vertex Pharmaceuticals, Inc. In her past career Dr. Bozic occupied the position of Senior Vice President-Global Development at Biogen, Inc. She received a doctorate from McGill University.

Mladen Božic

Rade Božic

Rade Božic has a current job as a Member-Management Board at Unis-Feros AD.

Kevin J.
Bozic is currently the Director at the American Academy of Orthopaedic Surgeons.
He has an undergraduate degree from Duke University, a doctorate from The University of California, San Francisco, and an MBA from Harvard Business School.

Dragutin Bozic

Davor Božic

No results for this search